ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

EVALUATE THE COMFORT AND VIABILITY OF SULFASALAZINE IN THE TREATMENT OF SEVERE ALOPECIA AREATA

Dr Iqra Zamir, Dr Amna Abbas, Dr Maryam Naeem

Objective: To evaluate the comfort and viability of sulfasalazine in healing of severe alopecia areata. Methods: Our current research was led at Sir Ganga Ram Hospital, Lahore from November 2017 to October 2018. This was a useful non-randomized, open-ended preliminary. A total of 45 subjects were recalled for review. Patients were selected from the branch of the Dermatology Unit II of the Sir Ganga Ram Hospital, Lahore. Subjects were observed with 500mg/day of sulfasalazine at a limit of 4 grams/day. The portion for the youngsters was 10mg/kg/day. Patients were followed up every two weeks. Reactive patients were followed for an additional 4 months. All important information was recorded and ventilated. Results: Four out of 64 patients (7%) responded to treatment. Two of these patients had a mid-reaction and two had a complete reaction. There was no significant gender contrast in the response to treatment. The significant symptom observed was the hepatotoxicity found in 5 patients resulting in suspension of the drug. Conclusion: Sulfasalazine is presumed to be moderately protected but not viable in the treatment of extreme AA. Keywords: Alopecia areata, alopecia total, alopecia universalis, sulphasalazine.

FULL TEXT